The Nef-infectivity enigma: Mechanisms of enhanced lentiviral infection

Current HIV Research

Volumn 9, Issue 7, 2011, Pages 474-489

  Vermeire, Jolien ^a   Vanbillemont, Griet ^a   Witkowski, Wojciech ^a   Verhasselt, Bruno ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Cholesterol; Envelope protein; HIV; Infectivity; Mutation analysis; Nef; Proteasome; Viral replication

Indexed keywords

CD4 ANTIGEN; CELL PROTEIN; LIPIDOME; NEF PROTEIN; VIRUS PROTEIN;

BIOGENESIS; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOMODULATION; LENTIVIRUS INFECTION; LIPID COMPOSITION; NONHUMAN; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN MOTIF; REVIEW; TRANSGENIC ORGANISM; VIRION; VIRUS INFECTIVITY; VIRUS MUTATION; VIRUS PARTICLE;

ANIMALS; GENE PRODUCTS, NEF; HIV; HIV-1; HUMANS; MACACA MULATTA; MUTATION; VIRION; VIRUS REPLICATION;

EID: 84856453839     PISSN: 1570162X     EISSN: 18734251     Source Type: Journal    
DOI: 10.2174/157016211798842099     Document Type: Review

References (130)

1. Joint United Nations Programme on HIV/AIDS (UNAIDS). Global report: UNAIDS report on the global AIDS epidemic 2010. 2010 [cited 2011 11th June]; Available from: http://www.unaids.org/documents /20101123_GlobalReport_em.pdf
2. Allers K, Hutter G, Hofmann J, et al. Evidence for the cure of HIV infection by CCR5Delta32/Delta32 stem cell transplantation. Blood 2011; 117: 2791-9.
3. Adamson CS and Freed EO. Novel approaches to inhibiting HIV-1 replication. Antiviral Res 2010; 85: 119-41.
4. Richter SN, Frasson I and Palu G. Strategies for inhibiting function of HIV-1 accessory proteins: a necessary route to AIDS therapy? Curr Med Chem 2009; 16: 267-86.
5. Malim MH and Emerman M. HIV-1 accessory proteins--ensuring viral survival in a hostile environment. Cell Host Microbe 2008; 3: 388-98.
6. Kestler HW, 3rd, Ringler DJ, Mori K, et al. Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell 1991; 65: 651-62.
7. Deacon NJ, Tsykin A, Solomon A, et al. Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science 1995; 270: 988-91.
8. Kirchhoff F, Greenough TC, Brettler DB, et al. Brief report: absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection. N Engl J Med 1995; 332: 228-32.
9. Salvi R, Garbuglia AR, Di CA, et al. Grossly defective nef gene sequences in a human immunodeficiency virus type 1-seropositive long-term nonprogressor. J Virol 1998; 72: 3646-57.
10. Gorry PR, McPhee DA, Verity E, et al. Pathogenicity and immunogenicity of attenuated, nef-deleted HIV-1 strains in vivo. Retrovirology 2007; 4: 66.
11. Zaunders J, Dyer WB and Churchill M. The Sydney Blood Bank Cohort: implications for viral fitness as a cause of elite control. Curr Opin HIV AIDS 2011; 6: 151-6.
12. Baba TW, Liska V, Khimani AH, et al. Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques. Nat Med 1999; 5: 194-203.
13. Hanna Z, Kay DG, Rebai N, et al. Nef harbors a major determinant of pathogenicity for an AIDS-like disease induced by HIV-1 in transgenic mice. Cell 1998; 95: 163-75.
14. Foster JL, Denial SJ, Temple BR and Garcia JV. Mechanisms of HIV-1 Nef Function and Intracellular Signaling. J Neuroimmune Pharmacol 2011; 6: 230-46.
15. Arien KK and Verhasselt B. HIV Nef: role in pathogenesis and viral fitness. Curr HIV Res 2008; 6: 200-8.
16. Arhel NJ and Kirchhoff F. Implications of Nef: host cell interactions in viral persistence and progression to AIDS. Curr Top Microbiol Immunol 2009; 339: 147-75.
17. Ahmad N and Venkatesan S. Nef protein of HIV-1 is a transcriptional repressor of HIV-1 LTR. Science 1988; 241: 1481-85.
18. Hammes SR, Dixon EP, Malim MH, et al. Nef protein of human immunodeficiency virus type 1: evidence against its role as a transcriptional inhibitor. Proc Natl Acad Sci USA 1989; 86: 9549-53.
19. Kim S, Ikeuchi K, Byrn R, et al. Lack of a negative influence on viral growth by the nef gene of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1989; 86: 9544-48.
20. Miller MD, Warmerdam MT, Gaston I, et al. The human immunodeficiency virus-1 nef gene product: a positive factor for viral infection and replication in primary lymphocytes and macrophages. J Exp Med 1994; 179: 101-13.
21. Spina CA, Kwoh TJ, Chowers MY, et al. The importance of nef in the induction of human immunodeficiency virus type 1 replication from primary quiescent CD4 lymphocytes. J Exp Med 1994; 179: 115-23.
22. Simmons A, Aluvihare V and McMichael A. Nef triggers a transcriptional program in T cells imitating single-signal T cell activation and inducing HIV virulence mediators. Immunity 2001; 14: 763-77.
23. Wang JK, Kiyokawa E, Verdin E and Trono D. The Nef protein of HIV-1 associates with rafts and primes T cells for activation. Proc Natl Acad Sci USA 2000; 97: 394-99.
24. Witte V, Laffert B, Gintschel P, et al. Induction of HIV transcription by Nef involves Lck activation and protein kinase C theta raft recruitment leading to activation of ERK1/2 but not NF kappa B. J Immunol 2008; 181: 8425-32.
25. Ross TM, Oran AE and Cullen BR. Inhibition of HIV-1 progeny virion release by cell-surface CD4 is relieved by expression of the viral Nef protein. Curr Biol 1999; 9: 613-21.
26. Haller C, Tibroni N, Rudolph JM, et al. Nef does not inhibit F-actin remodelling and HIV-1 cell-cell transmission at the T lymphocyte virological synapse. Eur J Cell Biol 2010. doi: 10.1016/j.ejcb.2010.09.010
27. Nobile C, Rudnicka D, Hasan M, et al. HIV-1 Nef inhibits ruffles, induces filopodia, and modulates migration of infected lymphocytes. J Virol 2010; 84: 2282-93.
28. Sol-Foulon N, Moris A, Nobile C, et al. HIV-1 Nef-induced upregulation of DC-SIGN in dendritic cells promotes lymphocyte clustering and viral spread. Immunity 2002; 16: 145-55.
29. Kimpton J and Emerman M. Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated betagalactosidase gene. J Virol 1992; 66: 2232-39.
30. Miller MD, Warmerdam MT, Page KA, et al. Expression of the human immunodeficiency virus type 1 (HIV-1) nef gene during HIV-1 production increases progeny particle infectivity independently of gp160 or viral entry. J Virol 1995; 69: 579-84.
31. Munch J, Rajan D, Schindler M, et al. Nef-mediated enhancement of virion infectivity and stimulation of viral replication are fundamental properties of primate lentiviruses. J Virol 2007; 81: 13852-64.
32. Aiken C, Konner J, Landau NR, et al. Nef induces CD4 endocytosis: requirement for a critical dileucine motif in the membrane-proximal CD4 cytoplasmic domain. Cell 1994; 76: 853-64.
33. Glushakova S, Munch J, Carl S, et al. CD4 down-modulation by human immunodeficiency virus type 1 Nef correlates with the efficiency of viral replication and with CD4(+) T-cell depletion in human lymphoid tissue ex vivo. J Virol 2001; 75: 10113-7.
34. Schindler M, Rajan D, Specht A, et al. Association of Nef with p21-activated kinase 2 is dispensable for efficient human immunodeficiency virus type 1 replication and cytopathicity in ex vivo-infected human lymphoid tissue. J Virol 2007; 81: 13005-14.
35. Neri F, Giolo G, Potesta M, et al. CD4 downregulation by the human immunodeficiency virus type 1 Nef protein is dispensable for optimal output and functionality of viral particles in primary T cells. J Gen Virol. 2011; 92: 141-50.
36. Welker R, Harris M, Cardel B and Krausslich HG. Virion incorporation of human immunodeficiency virus type 1 Nef is mediated by a bipartite membrane-targeting signal: analysis of its role in enhancement of viral infectivity. J Virol 1998; 72: 8833-40.
37. Pizzato M, Helander A, Popova E, et al. Dynamin 2 is required for the enhancement of HIV-1 infectivity by Nef. Proc Natl Acad Sci USA 2007; 104: 6812-17.
38. Miller MD, Warmerdam MT, Ferrell SS, et al. Intravirion generation of the C-terminal core domain of HIV-1 Nef by the HIV-1 protease is insufficient to enhance viral infectivity. Virology 1997; 234: 215-25.
39. Chen YL, Trono D and Camaur D. The proteolytic cleavage of human immunodeficiency virus type 1 Nef does not correlate with its ability to stimulate virion infectivity. J Virol 1998; 72: 3178-84.
40. Giese SI, Woerz I, Homann S, et al. Specific and distinct determinants mediate membrane binding and lipid raft incorporation of HIV-1(SF2) Nef. Virology 2006; 355: 175-91.
41. Liu LX, Heveker N, Fackler OT, et al. Mutation of a conserved residue (D123) required for oligomerization of human immunodeficiency virus type 1 Nef protein abolishes interaction with human thioesterase and results in impairment of Nef biological functions. J Virol 2000; 74: 5310-9.
42. Craig HM, Pandori MW and Guatelli JC. Interaction of HIV-1 Nef with the cellular dileucine-based sorting pathway is required for CD4 down-regulation and optimal viral infectivity. Proc Natl Acad Sci USA 1998; 95: 11229-34.
43. O'Neill E, Kuo LS, Krisko JF, et al. Dynamic evolution of the human immunodeficiency virus type 1 pathogenic factor, Nef. J Virol 2006; 80: 1311-20.
44. Stoddart CA, Geleziunas R, Ferrell S, et al. Human immunodeficiency virus type 1 Nef-mediated downregulation of CD4 correlates with Nef enhancement of viral pathogenesis. J Virol 2003; 77: 2124-33.
45. Wiskerchen M and Cheng-Mayer C. HIV-1 Nef association with cellular serine kinase correlates with enhanced virion infectivity and efficient proviral DNA synthesis. Virology 1996; 224: 292-301.
46. Goldsmith MA, Warmerdam MT, Atchison RE, et al. Dissociation of the CD4 downregulation and viral infectivity enhancement functions of human immunodeficiency virus type 1 Nef. J Virol 1995; 69: 4112-21.
47. Madrid R, Janvier K, Hitchin D, et al. Nef-induced alteration of the early/recycling endosomal compartment correlates with enhancement of HIV-1 infectivity. J Biol Chem 2005; 280: 5032-44.
48. Akari H, Arold S, Fukumori T, et al. Nef-induced major histocompatibility complex class I down-regulation is functionally dissociated from its virion incorporation, enhancement of viral infectivity, and CD4 down-regulation. J Virol 2000; 74: 2907-12.
49. Baugh LL, Garcia JV and Foster JL. Functional characterization of the human immunodeficiency virus type 1 Nef acidic domain. J Virol 2008; 82: 9657-67.
50. Fackler OT, Moris A, Tibroni N, et al. Functional characterization of HIV-1 Nef mutants in the context of viral infection. Virology 2006; 351: 322-39.
51. Jere A, Fujita M, Adachi A and Nomaguchi M. Role of HIV-1 Nef protein for virus replication in vitro. Microbes Infect 2010; 12: 65-70.
52. Lundquist CA, Tobiume M, Zhou J, et al. Nef-mediated downregulation of CD4 enhances human immunodeficiency virus type 1 replication in primary T lymphocytes. J Virol 2002; 76: 4625-33.
53. Aldrovandi GM, Gao L, Bristol G and Zack JA. Regions of human immunodeficiency virus type 1 nef required for function in vivo. J Virol 1998; 72: 7032-39.
54. Waheed AA and Freed EO. The Role of Lipids in Retrovirus Replication. Viruses 2010; 2: 1146-80.
55. Sol-Foulon N, Esnault C, Percherancier Y, et al. The effects of HIV-1 Nef on CD4 surface expression and viral infectivity in lymphoid cells are independent of rafts. J Biol Chem 2004; 279: 31398-408.
56. Brugger B, Krautkramer E, Tibroni N, et al. Human immunodeficiency virus type 1 Nef protein modulates the lipid composition of virions and host cell membrane microdomains. Retrovirology 2007; 4: 70.
57. Piguet V, Wan L, Borel C, et al. HIV-1 Nef protein binds to the cellular protein PACS-1 to downregulate class I major histocompatibility complexes. Nat Cell Biol 2000; 2: 163-7.
58. Fackler OT, Luo W, Geyer M, et al. Activation of Vav by Nef induces cytoskeletal rearrangements and downstream effector functions. Mol Cell 1999; 3: 729-39.
59. Fackler OT, Lu X, Frost JA, et al. p21-activated kinase 1 plays a critical role in cellular activation by Nef. Mol Cell Biol 2000; 20: 2619-27.
60. Chaudhuri R, Lindwasser OW, Smith WJ, et al. Downregulation of CD4 by human immunodeficiency virus type 1 Nef is dependent on clathrin and involves direct interaction of Nef with the AP2 clathrin adaptor. J Virol 2007; 81: 3877-90.
61. Arold S, Hoh F, Domergue S, et al. Characterization and molecular basis of the oligomeric structure of HIV-1 nef protein. Protein Sci 2000; 9: 1137-48.
62. Poe JA and Smithgall TE. HIV-1 Nef dimerization is required for Nef-mediated receptor downregulation and viral replication. J Mol Biol 2009; 394: 329-42.
63. Kwak YT, Raney A, Kuo LS, et al. Self-association of the Lentivirus protein, Nef. Retrovirology 2010; 7: 77.
64. Aiken C and Trono D. Nef stimulates human immunodeficiency virus type 1 proviral DNA synthesis. J Virol 1995; 69: 5048-56.
65. Welker R, Kottler H, Kalbitzer HR and Krausslich HG. Human immunodeficiency virus type 1 Nef protein is incorporated into virus particles and specifically cleaved by the viral proteinase. Virology 1996; 219: 228-36.
66. Pandori MW, Fitch NJ, Craig HM, et al. Producer-cell modification of human immunodeficiency virus type 1: Nef is a virion protein. J Virol 1996; 70: 4283-90.
67. Kogan M and Rappaport J. HIV-1 accessory protein Vpr: relevance in the pathogenesis of HIV and potential for therapeutic intervention. Retrovirology 2011; 8: 25.
68. Bukovsky AA, Dorfman T, Weimann A and Gottlinger HG. Nef association with human immunodeficiency virus type 1 virions and cleavage by the viral protease. J Virol 1997; 71: 1013-8.
69. Zheng YH, Plemenitas A, Fielding CJ and Peterlin BM. Nef increases the synthesis of and transports cholesterol to lipid rafts and HIV-1 progeny virions. Proc Natl Acad Sci USA 2003; 100: 8460-5.
70. Qi M and Aiken C. Nef enhances HIV-1 infectivity via association with the virus assembly complex. Virology 2008; 373: 287-97.
71. Laguette N, Benichou S and Basmaciogullari S. Human immunodeficiency virus type 1 Nef incorporation into virions does not increase infectivity. J Virol 2009; 83: 1093-104.
72. Khan M, Garcia-Barrio M and Powell MD. Restoration of wildtype infectivity to human immunodeficiency virus type 1 strains lacking nef by intravirion reverse transcription. J Virol 2001; 75: 12081-7.
73. Schwartz O, Marechal V, Danos O and Heard JM. Human immunodeficiency virus type 1 Nef increases the efficiency of reverse transcription in the infected cell. J Virol 1995; 69: 4053-9.
74. Arganaraz ER, Schindler M, Kirchhoff F, et al. Enhanced CD4 down-modulation by late stage HIV-1 nef alleles is associated with increased Env incorporation and viral replication. J Biol Chem. 2003; 278: 33912-9.
75. Lama J, Mangasarian A and Trono D. Cell-surface expression of CD4 reduces HIV-1 infectivity by blocking Env incorporation in a Nef-and Vpu-inhibitable manner. Curr Biol 1999; 9: 622-31.
76. Lundquist CA, Zhou J and Aiken C. Nef stimulates human immunodeficiency virus type 1 replication in primary T cells by enhancing virion-associated gp120 levels: coreceptor-dependent requirement for Nef in viral replication. J Virol 2004; 78: 6287-96.
77. Cortes MJ, Wong-Staal F and Lama J. Cell surface CD4 interferes with the infectivity of HIV-1 particles released from T cells. The Journal of biological chemistry 2002; 277: 1770-9.
78. Schiavoni I, Trapp S, Santarcangelo AC, et al. HIV-1 Nef enhances both membrane expression and virion incorporation of Env products. A model for the Nef-dependent increase of HIV-1 infectivity. J Biol Chem 2004; 279: 22996-006.
79. Swingler S, Gallay P, Camaur D, et al. The Nef protein of human immunodeficiency virus type 1 enhances serine phosphorylation of the viral matrix. J Virol 1997; 71: 4372-7.
80. Bhatia AK, Kaushik R, Campbell NA, et al. Mutation of critical serine residues in HIV-1 matrix result in an envelope incorporation defect which can be rescued by truncation of the gp41 cytoplasmic tail. Virology 2009; 384: 233-41.
81. Kaushik R and Ratner L. Role of human immunodeficiency virus type 1 matrix phosphorylation in an early postentry step of virus replication. J Virol 2004; 78: 2319-26.
82. Dorfman T, Popova E, Pizzato M and Gottlinger HG. Nef enhances human immunodeficiency virus type 1 infectivity in the absence of matrix. J Virol 2002; 76: 6857-62.
83. Cantin R, Methot S and Tremblay MJ. Plunder and stowaways: incorporation of cellular proteins by enveloped viruses. J Virol 2005; 79: 6577-87.
84. Saphire AC, Gallay PA and Bark SJ. Proteomic analysis of human immunodeficiency virus using liquid chromatography/tandem mass spectrometry effectively distinguishes specific incorporated host proteins. J Proteome Res 2006; 5: 530-8.
85. Impens F, Iannucci V, Ariën KK, et al. Protein processing during HIV-1 infection. Submitted.
86. Cantin R, Fortin JF, Lamontagne G and Tremblay M. The acquisition of host-derived major histocompatibility complex class II glycoproteins by human immunodeficiency virus type 1 accelerates the process of virus entry and infection in human Tlymphoid cells. Blood 1997; 90: 1091-100.
87. Martin G, Beausejour Y, Thibodeau J and Tremblay MJ. Envelope glycoproteins are dispensable for insertion of host HLA-DR molecules within nascent human immunodeficiency virus type 1 particles. Virology 2005; 335: 286-90.
88. Giguere JF, Bounou S, Paquette JS, et al. Insertion of host-derived costimulatory molecules CD80 (B7.1) and CD86 (B7.2) into human immunodeficiency virus type 1 affects the virus life cycle. J Virol 2004; 78: 6222-32.
89. Beausejour Y and Tremblay MJ. Envelope glycoproteins are not required for insertion of host ICAM-1 into human immunodeficiency virus type 1 and ICAM-1-bearing viruses are still infectious despite a suboptimal level of trimeric envelope proteins. Virology 2004; 324: 165-172.
90. Bounou S, Leclerc JE and Tremblay MJ. Presence of host ICAM-1 in laboratory and clinical strains of human immunodeficiency virus type 1 increases virus infectivity and CD4(+)-T-cell depletion in human lymphoid tissue, a major site of replication in vivo. J Virol 2002; 76: 1004-14.
91. Bresnahan PA, Yonemoto W, Ferrell S, et al. A dileucine motif in HIV-1 Nef acts as an internalization signal for CD4 downregulation and binds the AP-1 clathrin adaptor. Curr Biol 1998; 8: 1235-38.
92. Greenberg M, DeTulleo L, Rapoport I, et al. A dileucine motif in HIV-1 Nef is essential for sorting into clathrin-coated pits and for downregulation of CD4. Curr Biol 1998; 8: 1239-42.
93. Greenberg ME, Iafrate AJ and Skowronski J. The SH3 domainbinding surface and an acidic motif in HIV-1 Nef regulate trafficking of class I MHC complexes. EMBO J 1998; 17: 2777-89.
94. Janvier K, Craig H, Hitchin D, et al. HIV-1 Nef stabilizes the association of adaptor protein complexes with membranes. J Biol Chem 2003; 278: 8725-32.
95. Fan Y, Liu C, Qin X, et al. The role of ERK1/2 signaling pathway in Nef protein upregulation of the expression of the intercellular adhesion molecule 1 in endothelial cells. Angiology 2010; 61: 669-78.
96. Zheng YH, Plemenitas A, Linnemann T, et al. Nef increases infectivity of HIV via lipid rafts. Curr Biol 2001; 11: 875-9.
97. Brugger B, Glass B, Haberkant P, et al. The HIV lipidome: a raft with an unusual composition. Proc Natl Acad Sci USA 2006; 103: 2641-6.
98. Chan R, Uchil PD, Jin J, et al. Retroviruses human immunodeficiency virus and murine leukemia virus are enriched in phosphoinositides. J Virol 2008; 82: 11228-38.
99. van't Wout AB, Swain JV, Schindler M, et al. Nef induces multiple genes involved in cholesterol synthesis and uptake in human immunodeficiency virus type 1-infected T cells. J Virol 2005; 79: 10053-8.
100. Mujawar Z, Rose H, Morrow MP, et al. Human immunodeficiency virus impairs reverse cholesterol transport from macrophages. PLoS Biol 2006; 4: e365.
101. Morrow MP, Grant A, Mujawar Z, et al. Stimulation of the liver X receptor pathway inhibits HIV-1 replication via induction of ATPbinding cassette transporter A1. Mol Pharmacol 2010; 78: 215-25.
102. Campbell S, Gaus K, Bittman R, et al. The raft-promoting property of virion-associated cholesterol, but not the presence of virionassociated Brij 98 rafts, is a determinant of human immunodeficiency virus type 1 infectivity. J Virol 2004; 78: 10556-65.
103. Tobiume M, Tokunaga K, Kiyokawa E, et al. Requirement of nef for HIV-1 infectivity is biased by the expression levels of Env in the virus-producing cells and CD4 in the target cells. Arch Virol 2001; 146: 1739-51.
104. Chowers MY, Pandori MW, Spina CA, et al. The growth advantage conferred by HIV-1 nef is determined at the level of viral DNA formation and is independent of CD4 downregulation. Virology 1995; 212: 451-57.
105. Campbell EM, Nunez R and Hope TJ. Disruption of the actin cytoskeleton can complement the ability of Nef to enhance human immunodeficiency virus type 1 infectivity. J Virol 2004; 78: 5745-55.
106. Cavrois M, Neidleman J, Yonemoto W, et al. HIV-1 virion fusion assay: uncoating not required and no effect of Nef on fusion. Virology 2004; 328: 36-44.
107. Tobiume M, Lineberger JE, Lundquist CA, et al. Nef does not affect the efficiency of human immunodeficiency virus type 1 fusion with target cells. J Virol 2003; 77: 10645-50.
108. Schaeffer E, Geleziunas R and Greene WC. Human immunodeficiency virus type 1 Nef functions at the level of virus entry by enhancing cytoplasmic delivery of virions. J Virol 2001; 75: 2993-3000.
109. Aiken C. Pseudotyping human immunodeficiency virus type 1 (HIV-1) by the glycoprotein of vesicular stomatitis virus targets HIV-1 entry to an endocytic pathway and suppresses both the requirement for Nef and the sensitivity to cyclosporin A. J Virol 1997; 71: 5871-7.
110. Luo T, Douglas JL, Livingston RL and Garcia JV. Infectivity enhancement by HIV-1 Nef is dependent on the pathway of virus entry: implications for HIV-based gene transfer systems. Virology 1998; 241: 224-33.
111. Chazal N, Singer G, Aiken C, et al. Human immunodeficiency virus type 1 particles pseudotyped with envelope proteins that fuse at low pH no longer require Nef for optimal infectivity. J Virol 2001; 75: 4014-8.
112. Pizzato M, Popova E and Gottlinger HG. Nef can enhance the infectivity of receptor-pseudotyped human immunodeficiency virus type 1 particles. J Virol 2008; 82: 10811-9.
113. Yoder A, Yu D, Dong L, et al. HIV envelope-CXCR4 signaling activates cofilin to overcome cortical actin restriction in resting CD4 T cells. Cell 2008; 134: 782-92.
114. Daecke J, Fackler OT, Dittmar MT and Krausslich HG. Involvement of clathrin-mediated endocytosis in human immunodeficiency virus type 1 entry. J Virol 2005; 79: 1581-94.
115. Miyauchi K, Kim Y, Latinovic O, et al. HIV enters cells via endocytosis and dynamin-dependent fusion with endosomes. Cell 2009; 137: 433-44.
116. Permanyer M, Ballana E and Este JA. Endocytosis of HIV: anything goes. Trends Microbiol 2010; 18: 543-51.
117. Yu D, Wang W, Yoder A, et al. The HIV envelope but not VSV glycoprotein is capable of mediating HIV latent infection of resting CD4 T cells. PLoS Pathog 2009; 5: e1000633
118. Bukrinskaya A, Brichacek B, Mann A and Stevenson M. Establishment of a functional human immunodeficiency virus type 1 (HIV-1) reverse transcription complex involves the cytoskeleton. J Exp Med 1998; 188: 2113-25.
119. Warrilow D, Tachedjian G and Harrich D. Maturation of the HIV reverse transcription complex: putting the jigsaw together. Rev Med Virol 2009; 19: 324-37.
120. Schwartz EJ and Klotman PE. Pathogenesis of human immunodeficiency virus (HIV)-associated nephropathy. Semin Nephrol 1998; 18: 436-45.
121. Wei BL, Denton PW, O'Neill E, et al. Inhibition of lysosome and proteasome function enhances human immunodeficiency virus type 1 infection. J Virol 2005; 79: 5705-12.
122. Qi M and Aiken C. Selective restriction of Nef-defective human immunodeficiency virus type 1 by a proteasome-dependent mechanism. J Virol 2007; 81: 1534-6.
123. Chernomordik LV and Kozlov MM. Membrane hemifusion: crossing a chasm in two leaps. Cell 2005; 123: 375-82.
124. Melikyan GB. Common principles and intermediates of viral protein-mediated fusion: the HIV-1 paradigm. Retrovirology 2008; 5: 111.
125. Melikyan GB, Barnard RJ, Abrahamyan LG, et al. Imaging individual retroviral fusion events: from hemifusion to pore formation and growth. Proc Natl Acad Sci USA 2005; 102: 8728-33.
126. Kirchhoff F, Schindler M, Specht A, et al. Role of Nef in primate lentiviral immunopathogenesis. Cell Mol Life Sci 2008; 65: 2621-36.
127. Brenner M, Munch J, Schindler M, et al. Importance of the N-distal AP-2 binding element in Nef for simian immunodeficiency virus replication and pathogenicity in rhesus macaques. J Virol 2006; 80: 4469-81.
128. Iafrate AJ, Carl S, Bronson S, et al. Disrupting surfaces of nef required for downregulation of CD4 and for enhancement of virion infectivity attenuates simian immunodeficiency virus replication in vivo. J Virol 2000; 74: 9836-44.
129. Pizzato M. MLV glycosylated-Gag is an infectivity factor that rescues Nef-deficient HIV-1. Proc Natl Acad Sci USA 2010; 107: 9364-69.
130. Derdeyn CA, Decker JM, Sfakianos JN, et al. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virol 2000; 74: 8358-67.